Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ombitasvir/ABT-450/ritonavir plus sofosbuvir with or without ribavirin in genotype 2 or 3 chronic HCV
2014-003147-35Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ombitasvir, paritaprevir, ritonavir, sofosbuvir, ribavirin in chronic hepatitis C (CHC), sponsored by AbbVie Inc.. Started Oct 2014; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirsofosbuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2014-003147-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003147-35.